PSG
23.1.2024 09:01:30 CET | Business Wire | Press release
Visit Group, a market-leading, Nordic-based, hospitality and travel software company, today announced more than €100 million in strategic growth investment from PSG Equity (“PSG”), a leading growth equity firm partnering with software and technology-enabled services companies to help accelerate their growth. PSG is acquiring a majority stake in the company.
Headquartered in Gothenburg, Sweden, Visit Group is a market leader in the Nordics within hospitality and travel technology, providing collaborative commerce software to in-destination experience vendors, including lodgings, day tours and attractions, mountain resorts, ferry operators, amusement parks and activity vendors. As of August 2023, the company serves more than 2,200 customers in over 25 countries. Visit Group’s multiple software solutions create a unique ecosystem that helps hospitality and travel providers package, sell, distribute, and deliver excellent guest experiences.
With PSG’s support, Visit Group will invest to help accelerate both organic and inorganic growth across the region by broadening the range and depth of solutions offered to its customers.
“As a product-led business with high ambitions to make a real difference in the development of the hospitality industry, we believe that we have found the right partner for both continuing to strengthen our offer, and to accelerate our growth in and outside the Nordics. I believe that we will get the best of both worlds with our product building DNA and PSG’s experience in areas like M&A and growth operations,” said James Dixon, CEO of Visit Group.
“We’ve been in dialogues with several potential international partners for the next step in our growth journey. During this process, PSG has demonstrated some of the best understanding for what we are building, and we share the vision of the digital ecosystem for the hospitality industry. From the start, our customer-centric approach to innovation and our focus on building a scalable business with a good balance between growth and profitability have been our keys to success, and we aim to hang on to those values going forward,” said Magnus Emilson, founder and Executive Chairman of Visit Group.
The transaction marks PSG’s first platform investment in Sweden and Norway and its twenty-fourth in Europe. Under the terms of the investment, PSG will acquire shares in Visit Group from Standout Capital, a leading Nordic technology investor, and other minority shareholders while the founder and management will remain significant owners.
“We’ve been closely monitoring this space for some time and have been impressed by Visit Group’s unique value proposition across the Nordics, underpinned by strong network effects which help enhance connectivity and synergies among all stakeholders in the hospitality ecosystem,” said Edward Hughes, Managing Director at PSG. “We’re delighted to partner with Magnus and the team, bringing our sector expertise and experience to support them in achieving their mission of becoming one of the go-to software providers in European hospitality and travel.”
Houlihan Lokey acted as financial advisor to PSG Equity with MCF Corporate Finance acting as financial advisor to Visit Group.
ABOUT VISIT GROUP
Visit Group was founded by Magnus Emilson in Gothenburg in 1999. With 175 employees in seven countries and more than 2,200 customers across 25 countries as of August 2023, the group is a leading hospitality SaaS company in Northern Europe. With its collaborative commerce platform, the group serves providers of all types of lodging, ski resorts, activities, day tours, theme parks, museums, DMOs, ferry companies as well as resellers and agents. Visit Group’s platform optimizes customers’ sales, dynamic packaging, distribution as well as operational efficiency. To learn more about Visit Group, visit www.visitgroup.com.
ABOUT PSG
PSG is a growth equity firm that partners with software and technology-enabled services companies to help them navigate transformational growth, capitalize on strategic opportunities and build strong teams. Having backed more than 130+ companies and facilitated over 470+ add-on acquisitions, PSG brings extensive investment experience, deep expertise in software and technology, and a firm commitment to collaborating with management teams. Founded in 2014, PSG operates out of offices in Boston, Kansas City, London, Madrid, Paris and Tel-Aviv. To learn more about PSG, visit www.psgequity.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240122579024/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 14:00:00 CEST | Press release
Fuel manufactured at Springfields has generated enough energy to supply the UK’s electricity demand for 26 years, avoiding the emission of nearly 3 billion tonnes of CO2 The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 5
HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 14:00:00 CEST | Press release
HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
Samsung Biologics Strike: Labor Union Warns of CDMO Supply Chain Risks Following Overwhelming Vote30.3.2026 11:52:00 CEST | Press release
Union members overwhelmingly approve strike action with 95.52% voting in favor on a 95.38% turnout, clearing the final legal hurdle after mediation ceased.Union emphasizes this is a fight against structural corporate governance issues, citing unresolved allegations concerning unfair labor practices and ESG compliance risks.Management adhered to a group-level wage guideline rather than bargaining on the basis of Samsung Biologics' own performance, exposing a lack of independent bargaining authority. The Samsung Biologics Labor Union (President: Jaesung Park), representing approximately 75% of the company's total employees, announced today that its members have overwhelmingly voted in favor of a strike, with 95.52% voting in favor on a 95.38% turnout during a voting period from March 24 to March 29. Following the Incheon Regional Labor Relations Commission's decision to cease mediation, the union has now secured the legal mandate to strike. The union stressed that this strike is not mere
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom